Navigation Links
New treatment for kala azar, the most deadly parasitic disease after malaria
Date:9/23/2011

[Nairobi, 23 September 2011] East Africa is fighting the worst kala azar outbreak in a decade. Collaboration across the region through the Leishmaniasis East Africa Platform (LEAP) has resulted in the development of a new combination therapy (SSG&PM) which is cheaper and nearly halves the length of treatment from a 30 day course of injections to 17 days. East African endemic countries are taking the necessary regulatory measures to use it in their programmes, but experts warn that without international funding or interest in supporting governments in the roll out, too few patients will benefit.

"The poorest of the poor, in the most remote villages are the ones who are wasting away from kala azar and who could benefit the most from a shorter more affordable treatment" said Dr. Monique Wasunna, Assistant Director, KEMRI, and Head, DNDi Africa. "Neglected diseases and patients mean that even when there are new treatments and hope, they are too far from the headlines and donor priorities to get support to governments. This is why we are calling for urgent action."

This week in Nairobi, over 100 clinical researchers and regional experts from Ministries of Health and drug regulatory authorities are meeting for the bi-annual LEAP Leishmaniasis East Africa Platform to see what is and is not working in the field and to find better ways to control the disease.

After 70 years of little improvement or change in the treatment of kala azar in Africa, LEAP and its partners have developed a new treatment: Sodium Stibogluconate & Paromomycin (SSG&PM) combination treatment. This is cheaper and nearly halves the length of treatment from the current 30 day course of injections to 17 days. It also cures the patient. Combination therapies help fight resistance to treatment. Countries around the region are in the process of registration and are ready to use the treatment, but need funding to control the disease.

Kala azar is another name given to visceral leishmaniasis (VL), a parasitic disease endemic in around 70 countries worldwide. South Sudan has the second highest number of cases after India. The disease is spread through the bite of a sandfly and is fatal without treatment. Approximately half a million people are infected with the disease and 50-60,000 die every year as a result of the infection. Patients suffer from irregular bouts of fever, substantial weight loss, swelling of the spleen and liver, and anaemia.

"I have spent fifty years treating kala azar patients and researching this killer parasite and I know first-hand how desperately these poor patients and overburdened health workers need shorter, cheaper, and easier-to-use treatment," said Professor Ahmed Mohamed El Hassan, Emeritus Professor, Institute of Endemic Diseases University of Khartoum, Sudan. "Ideally for patients in such conditions, we need an oral treatment, such as those being tested or completely new drugs, but we are a long way from there and we need to make the most of this existing better treatment and find the funds to roll it out," he concluded.

In March 2010, the World Health Organization (WHO) Expert Committee on the Control of Leishmaniases recommended SSG&PM as first-line treatment for VL in East Africa. It is already being used to treat patients in the countries such as Sudan and South Sudan. Other affected countries are in the process of registering PM to combine it with the already registered SSG to get the treatment to patients.

"After 20 years, WHO has updated the guidelines for the control of leishmaniasis. This shows that there is greater collaboration and progress. Now countries need support to translate this into lives saved on the ground," said Dr. Merc Herrero, Disease Prevention and Control, Leishmaniasis National Control Programme, WHO Ethiopia.

The development of SSG&PM is the result of a collaborative partnership over a period of six years between DNDi, LEAP, and other partners including the National Control Programmes of Kenya, Sudan, Ethiopia, and Uganda, as well as Mdecins Sans Frontires (MSF) and the World Health Organization (WHO).


'/>"/>

Contact: Violaine Daellenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Related medicine news :

1. Heart drug offers possible treatment for patients facing respiratory failure
2. Elderly breast cancer patients risk treatment discrimination
3. University of Kentucky spinoff licensed to develop Alzheimers treatment
4. UT awarded NIH grants to study prevention and treatment of neurodegenerative and vascular diseases
5. Continued treatment for lupus may boost survival of those patients with end-stage kidney disease
6. Emergency treatment for heart attack improving but delays still occur
7. One-Third of Severe Heart Attack Patients Have Treatment Delays
8. Two Varicose Veins Treatments Equally Effective
9. T cells making brain chemicals may lead to better treatments for inflammation, autoimmune diseases
10. Estrogen treatment may help reverse severe pulmonary hypertension
11. Tailored Hepatitis C Therapy May Cut Treatment Time in Half
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... ... Today, FloSports , a global leader in live digital sports and ... a long-term extension of their media partnership. The partnership, which began in 2013, will ... premier events exclusively on FloWrestling.com as well as usage of the FloArena meet management ...
(Date:1/16/2017)... Costa Mesa, California (PRWEB) , ... January 16, 2017 , ... ... Since 2014, Dr. Beazley has served on CalSouthern’s Board of Trustees and as a ... Sciences. In addition, he has been a professor of psychology at Pepperdine University, where ...
(Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking for ... new video released by Serenity Recovery, a holistic treatment center for addiction located in ... features footage and testimonials from patients and staff that visited the 2016 Recovery Palooza ...
(Date:1/16/2017)... ... January 16, 2017 , ... ... the newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Board-certified oculoplastic ... Journal , the official journal of The American Society for Aesthetic Plastic Surgery, ... The procedure is designed to correct drooping, retracted lower eyelids, which usually result ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... YORK , Jan. 16, 2017 ... Densitometers Market Outlook to 2022", provides key market data ... provides value, in millions of US dollars, volume (in ... Dual Energy X-Ray Absorptiometry (DEXA) and Quantitative Ultrasound (QUS). ... shares data for each of these market segements, and ...
(Date:1/16/2017)... 16, 2017 The global pacemaker market is ... to a new report by Grand View Research, Inc. ... availability of medical coverage is a key driving factor ... enhancements in these devices are supporting the expansion of ... is a high-impact growth rendering driver for this market. ...
(Date:1/16/2017)...   The Harrington Discovery Institute at ... , has announced the 2017 recipients of Harrington ... physician-scientists whose research shows promise to advance the ... Institute – part of The Harrington Project for ... academic medicine: to advance early breakthroughs into the ...
Breaking Medicine Technology: